Company Overview
Company Type: Private Company
Website: www.patternpharma.com
Number of Employees: -
Year Founded: 2018
Total Amount Raised (CAD mm)†: 2.96
Total Rounds of Funding**:5
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Pattern Pharma Inc. produces vaccines against infectious diseases and oncology indications. The company offers P2PAR, an immunotherapy product that activates the innate immune cells, including dendritic cells, macrophages, and natural killer cells to fight infectious diseases and cancer. Pattern Pharma Inc. was incorporated in 2018 and is based in Toronto, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Frans van Coeverden de Groot, Mark 
President, CEO & Director
Williams, Andrew 
Chief Financial Officer
Glover, Nicholas R.
Executive Director

Key Board Members
Name
Title
Frans van Coeverden de Groot, Mark 
President, CEO & Director
Glover, Nicholas R.
Executive Director
Keirstead, Hans S.
Director


Primary Industry Classification
Pharmaceuticals


Primary Office Location
31 Ridge Drive | Toronto, ON | M4T 1B6 | Canada
Phone: 416 302 5155   

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Fight Against Cancer Innovation Trust, Investment Arm
-
Unknown
-
-
MaRs Discovery District, Investment Arm
-
Unknown
-
-


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jul-06-2021
Jul-28-2021
Private Placement
Target
Pattern Pharma Inc.


1.50
May-14-2021
May-26-2021
Private Placement
Target
Pattern Pharma Inc.


0.15
Jul-30-2020
Sep-23-2020
Private Placement
Target
Pattern Pharma Inc.


0.57
Dec-18-2019
Jan-15-2020
Private Placement
Target
Pattern Pharma Inc.


0.10
Nov-12-2018
Nov-27-2018
Private Placement
Target
Pattern Pharma Inc.


0.04
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jul-28-2021
Private Placements
Pattern Pharma Inc. announced that it has received $1.498325 million in funding
Jul-06-2021
Private Placements
Pattern Pharma Inc. announced that it expects to receive $0.983325 million in funding
May-26-2021
Private Placements
Pattern Pharma Inc. announced that it has received $0.15 million in funding
May-14-2021
Private Placements
Pattern Pharma Inc. announced that it expects to receive $0.15 million in funding
Nov-10-2020
Company Conference Presentations
Pattern Pharma Inc. Presents at 2020 Texas Life Science Forum Conference, Nov-10-2020 through Nov-12-2020


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
Infinata, Inc.
Infinata Research
Jan 15, 2021 02:16 AM
Pattern Pharma Inc.
Pattern Pharma Inc. - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Dec 15, 2020 06:49 AM
Pattern Pharma Inc.
Pattern Pharma Inc. - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Sep 15, 2020 07:10 AM
Pattern Pharma Inc.
Pattern Pharma Inc. - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Jun 23, 2020 06:07 AM
Pattern Pharma Inc.
Pattern Pharma Inc. - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Mar 19, 2020 06:34 AM
Pattern Pharma Inc.
Pattern Pharma Inc. - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Dec 23, 2019 04:40 AM
Pattern Pharma Inc.
Pattern Pharma Inc. - Company Report
Reports
8
Infinata, Inc.
Infinata Research
Sep 30, 2019 05:53 AM
Pattern Pharma Inc.
Pattern Pharma Inc. - Company Report
Reports
8


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Board Members Details
Name
Title
Phone
Fax
Email
Frans van Coeverden de Groot, Mark 
President, CEO & Director
416 302 5155
-

Glover, Nicholas R.
Executive Director
416 302 5155
-
nglover@pronai.com
Keirstead, Hans S.
Director
416 302 5155
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Frans van Coeverden de Groot, Mark 
President, CEO & Director
416 302 5155
-

Williams, Andrew 
Chief Financial Officer
416 302 5155
-

Glover, Nicholas R.
Executive Director
416 302 5155
-
nglover@pronai.com
* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
